Reconstituting the Reverse
Cholesterol Transport Pathway
and LipimetiX, LLC, a privately held biopharmaceutical company, to develop a class of drugs to treat severely high cholesterol and triglyceride levels in patients that are not responsive to currently available therapies, and to treat acute coronary syndrome by rapidly decreasing arterial cholesterol content and inflammation.
LipimetiX' technology is based upon small peptide mimetics of Apolipoprotein E, a critical protein that directs cholesterol and triglyceride rich lipoproteins to receptors on the liver.
LipimetiX' lead preptide, AEM-28, is being developed for genetically induced refractory hypercholesterolemia, an orphan indication that leads to early cardiovascular disease.
LipimetiX Development, LLC.
is a joint venture between